The missing public-health infrastructure

India has roads, power and water. It is missing the infrastructure for infectious disease.

We are building it — a national network of molecular nodes that returns a syndromic PCR result in under one hour, with TB-with-drug-resistance capped at ₹749 nationwide, and feeds every anonymised result into a real-time, pathogen-level surveillance layer aligned to NCDC's IDSP. Catch disease early. Guide the right treatment. Watch over 1.4 billion.

Right diagnosis. Right antibiotic. First time.

Partner with us Find a node

Live surveillance signals

Nodes operational

Tests delivered

Cases found

Antibiotic courses averted

The problem

Four gaps. One national failure.

TB is a matter of national security. The diagnostic gap fuels an antimicrobial-resistance crisis — and a country that sees symptoms but not pathogens cannot get ahead of its outbreaks.

25% / 32%

TB as national security

India carries 25% of the world's TB burden and 32% of its multidrug-resistant TB — a public-health and economic threat at national scale.

Empirical first

The AMR crisis

With no fast, affordable answer, antibiotics are prescribed empirically. India is among the world's largest misusers — accelerating antimicrobial resistance.

9,000 labs

The diagnostic vacuum

Just ~9,000 molecular labs for 1.4 billion people. A private test costs ₹3,000 and a confirmed answer can take 30 days.

Symptom, not pathogen

The surveillance blind spot

NCDC / IDSP sees syndromes — fever, cough, diarrhoea — but rarely the pathogen behind them. The country counts symptoms, not the organisms driving outbreaks.

25%

of the world's TB burden carried by India

32%

of the world's MDR-TB is in India

₹3,000

cost of a molecular test in the private market

30 days

average delay to a confirmed diagnosis

9,000

molecular labs for 1.4 billion people

The patient journey today

Thirty days from first symptom to a confirmed answer — each stage compounding cost, transmission and resistance.

Day 0
1Symptom onset
Cough, fever, fatigue. Treated symptomatically at a local pharmacy.
Day 3
2Empirical antibiotics
A broad-spectrum course is prescribed without a confirmed cause.
Day 10
3No improvement
Patient returns; a second antibiotic is added. Still no diagnosis.
Day 18
4Referral
Sent to a distant facility for a ₹3,000 molecular test.
Day 30
5Confirmed diagnosis
TB confirmed — a month late, after the disease has spread.

The network

Three formats. One national grid.

Every node is a different shape of the same infrastructure — sized to the place it serves, connected to the same surveillance backbone.

Compact molecular micro-laboratory in an urban Indian neighborhood

Live · Sangam Vihar, Delhi

Hyperlocal Micro-Lab

A small-footprint node inside the community it serves. Walk-in testing, results in under an hour, priced for the neighborhood.

Container-based mobile diagnostic laboratory unit

Live · NITRD, New Delhi

IVD Yodha Mobile

A container-based unit that brings molecular PCR to where there is none — outreach, surge response and last-mile reach.

High-throughput molecular diagnostics laboratory interior

Live · Gurugram

Center of Excellence

A high-throughput hub anchoring a region: validation, training and the backbone capacity behind the network of nodes.

The destination state

50,000 nodes by 2030.

Three sites are live today — a Center of Excellence in Gurugram, the first Hyperlocal Micro-Lab in Sangam Vihar, and a Mobile unit at NITRD. Each new node lights the map a little brighter.

Operational today

50,000

Target by 2030

Operational node Planned node

Loading network map…

Operational nodes pulse in coral; planned nodes mark the constellation still to come.

The pipeline

TB first. NCDC syndromic next. The full menu by 2030.

The same node, the same hardware, the same chemistry — a phased rollout where each phase funds the next.

Phase 1

Active

Now → 2027

TB eradication

Test menu: TB-with-drug-resistance at ₹749 — a nationwide price cap, on every node.
Geography: The full hyperlocal node footprint, deployed around TB Yodha first.
Funding: Grant-funded.

₹749

TB + resistance, capped nationwide

Phase 2

From 2027

NCDC syndromic panels launch

Test menu: Acute Respiratory, Febrile, Diarrheal & Encephalitis syndromes, dengue, hepatitis, enteric fevers and the rest of the NCDC / IDSP-priority pathogens.
Geography: The same nodes, the same patient flow, the same price tier.
Funding: Funded entirely by Phase 1 operating surplus — zero new grant.

New grant required

Phase 3

By 2030

The full 80+ pathogen menu

Test menu: Every NCDC-priority disease covered; multi-pathogen panels across the syndromic suite.
Geography: Integrated with IDSP — the network becomes the country's pathogen-level surveillance backbone.
Funding: Self-sustaining network operations.

80+

Pathogens covered

“Same node. Same hardware. Phased pipeline. One grant seeds three phases.”

The second mission

Diagnosis is half the work. Stewardship is the other half.

Every empirical antibiotic prescribed without a diagnosis is a small contribution to the resistance crisis. A confirmed answer replaces the guess — and the unnecessary course.

IVD Yodha treats antimicrobial resistance as co-equal with diagnosis. Every test ends not with a result but with guidance: a consultant advising the right therapy, or the confidence to withhold an antibiotic that was never needed.

Empirical prescribing is replaced by evidence. That is how a diagnostic network becomes a stewardship network.

~70%

of antibiotics prescribed in India are estimated to be unnecessary or empirical — issued without a confirmed diagnosis.

1 test

is all it takes to turn a guess into a decision — and to keep one more antibiotic course in reserve for when it is truly needed.

Track record

We have built this before. At national scale.

The COVID-19 response was the proof of concept for express, affordable molecular diagnostics in India. IVD Yodha is that capability, turned toward the country's endemic burden.

₹199

The world's most affordable COVID-19 kit

The team engineered an RT-PCR kit at a price point no one else matched — proving affordability and quality are not a trade-off.

₹4,000 → ₹299

A national price correction

The market price of a COVID test fell from ₹4,000 to ₹299 — a correction this team catalysed and the country benefited from.

1st

India's first mobile RT-PCR network

Inaugurated by Union Home Minister Shri Amit Shah — the precedent for the IVD Yodha Mobile format.

100,000/day

The PathStore mega-lab, Gurugram

A high-throughput facility processing up to 100,000 samples a day — the backbone capacity behind a national network.

Indo-French strategic partnership

GeneStore France SASEradicus IndiaValidated at NITRD

A cross-border collaboration uniting French molecular engineering with Indian manufacturing and clinical validation — the foundation of the CITA platform.

Get involved